Resorption bone increased, Nerve injury, Eye injury
Drugs: KISUNLA
- Safetyreportversion
- 1
- Safetyreportid
- 26940073
- Primarysourcecountry
- US
- Occurcountry
- US
- Transmissiondateformat
- 102
- Transmissiondate
- 20260709
- Reporttype
- 1
- Serious
- 2
- Seriousnessdeath
- 2
- Seriousnesslifethreatening
- 2
- Seriousnesshospitalization
- 2
- Seriousnessdisabling
- 2
- Seriousnesscongenitalanomali
- 2
- Seriousnessother
- 2
- Receivedateformat
- 102
- Receivedate
- 20260630
- Receiptdateformat
- 102
- Receiptdate
- 20260630
- Fulfillexpeditecriteria
- 2
- Companynumb
- US-ELI_LILLY_AND_COMPANY-US202606030712
- Primarysource
- Reportercountry
- US
- Qualification
- 5
- Sender
- Sendertype
- 6
- Senderorganization
- ELI LILLY AND CO
- Receiver
- Receivertype
- 6
- Receiverorganization
- FDA
- Patient
- Patientsex
- 2
- Reaction
- Reactionmeddraversionpt
- 29.0
- Reactionmeddrapt
- Resorption bone increased
- Reactionoutcome
- 6
- Reactionmeddraversionpt
- 29.0
- Reactionmeddrapt
- Nerve injury
- Reactionoutcome
- 6
- Reactionmeddraversionpt
- 29.0
- Reactionmeddrapt
- Eye injury
- Reactionoutcome
- 6
- Drug
- Drugcharacterization
- 1
- Medicinalproduct
- KISUNLA
- Drugauthorizationnumb
- 761248
- Drugseparatedosagenumb
- 1
- Drugdosagetext
- UNK, UNKNOWN
- Drugindication
- Product used for unknown indication
- Actiondrug
- 5
- Drugadditional
- 3
- Activesubstance
- Activesubstancename
- DONANEMAB-AZBT
- Harmonized identifiers (openFDA)
- Application number
- BLA761248
- Brand name
- KISUNLA
- Generic name
- DONANEMAB-AZBT
- Manufacturer name
- Eli Lilly and Company
- Product NDC
- 0002-9401
- Product type
- HUMAN PRESCRIPTION DRUG
- Route
- INTRAVENOUS
- Substance name
- DONANEMAB
- RxCUI
- 2687972, 2687979
- SPL ID
- 85d3d68b-57f9-45e6-a1a7-fa19bc843f33
- SPL set ID
- 190352d4-ef62-4679-b4fa-e846e2766afa
- Package NDC
- 0002-9401-01
- UNII
- 1ADB65P1KK
